{"id":11401,"date":"2025-09-16T10:00:53","date_gmt":"2025-09-16T08:00:53","guid":{"rendered":"https:\/\/sitpharma.com\/italy\/?p=11401"},"modified":"2025-09-16T10:56:16","modified_gmt":"2025-09-16T08:56:16","slug":"sit-pharma-acquires-ostidil-d3-and-keforal","status":"publish","type":"post","link":"https:\/\/sitpharma.com\/italy\/en\/news-eng\/sit-pharma-acquires-ostidil-d3-and-keforal\/","title":{"rendered":"SIT PHARMA acquires OSTIDIL-D3 and KEFORAL"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"11401\" class=\"elementor elementor-11401\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-4351830 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"4351830\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-d8f5931\" data-id=\"d8f5931\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-15dbc11 elementor-widget elementor-widget-text-editor\" data-id=\"15dbc11\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>SIT PHARMA is pleased to announce the acquisition of OSTIDIL-D3 and KEFORAL\n<ol><li>OSTIDIL-D3 is indicated for the treatment of:<ul>\n<li>Osteodystrophy due to renal insufficiency requiring or not dialysis;<\/li>\n<li>Hypoparathyroidism;<\/li>\n<li>Rickets and vitamin D resistant or dependent (pseudo deficit) osteomalacia;<\/li>\n<li>Rickets and osteomalacia from renal conditions due to vitamin D metabolism;<\/li>\n<li>Post-menopausal osteoporosis.<\/li>\n<\/ul><\/li><br>\n<li>KEFORAL is indicated for the management of:<\/li>\n<ul><li>Respiratory tract infections caused by <em>St.pneumoniae<\/em> and beta-haemolytic Streptococcus (group A);<\/li>\n<li>Otitis media caused by <em>St. pneumoniae, H. influenzae<\/em>, staphylococci, streptococci and <em>M. catarrhalis<\/em>;<\/li>\n<li>Osteoarticular infections caused by staphylococci and\/or <em>P. mirabilis<\/em>;<\/li>\n<li>Skin or soft tissue infections caused by staphylococcus and\/or streptococci;<\/li>\n<li>Urinary tract infections, including acute prostatitis, caused by <em>Escherichia Coli, Pr. Mirabilis<\/em>, and <em>Klebsiella sp<\/em>;<\/li>\n<li>Dental infections due to staphylococci and streptococci;<\/li>\n<li>Bacterial sinusitis due to streptococcus, pneumococcus (<em>D. pneumoniae<\/em>) and <em>St. aureus<\/em> (only methicillin-sensitive).<\/li>\n<\/ul>\n<\/ol><\/p>\n<p>Silvia Lunati, SIT Pharma\u2019s General Manager, comments: \u201c<strong>The acquisition of OSTIDIL-D3 and KEFORAL confirms our desire to enrich our Italian portfolio and to guarantee physicians and patients the best solutions for the treatment and prevention of widespread pathologies, in clinical areas not yet covered by us<\/strong>\u201d.<\/p>\n\n<p>SIT Pharma is an Italian-based pharmaceutical group with presence in over 70 countries which develops, produces and commercializes more than 80 branded pharmaceutical products, Medical Devices and Food supplements<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-d313160 elementor-widget elementor-widget-text-editor\" data-id=\"d313160\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<h2 style=\"color: #2a4f88;\"><strong>About SIT PHARMA <\/strong><\/h2><p>SIT Pharma is a family-owned international pharmaceutical company, based in Italy since 1927, and today is an international pharmaceutical group with almost 100 years of experience and a recent history of prestigious acquisitions and global expansion. SIT Pharma is a reliable preferred acquirer for pharma businesses choosing to divest their \u201cmature,\u201d \u201cestablished\u201d or \u201ctail\u201d off-patent branded medicines.<\/p><p>In its two Italian manufacturing plants, SIT Pharma continues the high-quality \u201cMade in Italy\u201d drug manufacturing and management, aspiring to breathe new life into medicines, investing in them to renew the lifecycle and give new stability and sustainability over the long-term.<\/p><p>For more information, please visit our website www.sitpharma.com<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>SIT PHARMA is pleased to announce the acquisition of OSTIDIL-D3 and KEFORAL<\/p>\n","protected":false},"author":2,"featured_media":11016,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[95],"tags":[],"class_list":["post-11401","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-eng"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.1 (Yoast SEO v28.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>SIT PHARMA acquires OSTIDIL-D3 and KEFORAL - Sitpharma - Italia<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/sitpharma.com\/italy\/en\/news-eng\/sit-pharma-acquires-ostidil-d3-and-keforal\/\" \/>\n<meta property=\"og:locale\" content=\"it_IT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SIT PHARMA acquires OSTIDIL-D3 and KEFORAL\" \/>\n<meta property=\"og:description\" content=\"SIT PHARMA is pleased to announce the acquisition of OSTIDIL-D3 and KEFORAL\" \/>\n<meta property=\"og:url\" content=\"https:\/\/sitpharma.com\/italy\/en\/news-eng\/sit-pharma-acquires-ostidil-d3-and-keforal\/\" \/>\n<meta property=\"og:site_name\" content=\"Sitpharma - Italia\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-16T08:00:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-16T08:56:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/sitpharma.com\/italy\/wp-content\/uploads\/sites\/2\/2025\/04\/press-release-Sit-Pharma.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"pipestaff\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Scritto da\" \/>\n\t<meta name=\"twitter:data1\" content=\"pipestaff\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tempo di lettura stimato\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minuti\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/sitpharma.com\\\/italy\\\/en\\\/news-eng\\\/sit-pharma-acquires-ostidil-d3-and-keforal\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/sitpharma.com\\\/italy\\\/en\\\/news-eng\\\/sit-pharma-acquires-ostidil-d3-and-keforal\\\/\"},\"author\":{\"name\":\"pipestaff\",\"@id\":\"https:\\\/\\\/sitpharma.com\\\/italy\\\/#\\\/schema\\\/person\\\/351eae45371e9c78d10686173578ea00\"},\"headline\":\"SIT PHARMA acquires OSTIDIL-D3 and KEFORAL\",\"datePublished\":\"2025-09-16T08:00:53+00:00\",\"dateModified\":\"2025-09-16T08:56:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/sitpharma.com\\\/italy\\\/en\\\/news-eng\\\/sit-pharma-acquires-ostidil-d3-and-keforal\\\/\"},\"wordCount\":329,\"publisher\":{\"@id\":\"https:\\\/\\\/sitpharma.com\\\/italy\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/sitpharma.com\\\/italy\\\/en\\\/news-eng\\\/sit-pharma-acquires-ostidil-d3-and-keforal\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/sitpharma.com\\\/italy\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2025\\\/04\\\/press-release-Sit-Pharma.jpg\",\"articleSection\":[\"News-eng\"],\"inLanguage\":\"it-IT\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/sitpharma.com\\\/italy\\\/en\\\/news-eng\\\/sit-pharma-acquires-ostidil-d3-and-keforal\\\/\",\"url\":\"https:\\\/\\\/sitpharma.com\\\/italy\\\/en\\\/news-eng\\\/sit-pharma-acquires-ostidil-d3-and-keforal\\\/\",\"name\":\"SIT PHARMA acquires OSTIDIL-D3 and KEFORAL - Sitpharma - Italia\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/sitpharma.com\\\/italy\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/sitpharma.com\\\/italy\\\/en\\\/news-eng\\\/sit-pharma-acquires-ostidil-d3-and-keforal\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/sitpharma.com\\\/italy\\\/en\\\/news-eng\\\/sit-pharma-acquires-ostidil-d3-and-keforal\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/sitpharma.com\\\/italy\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2025\\\/04\\\/press-release-Sit-Pharma.jpg\",\"datePublished\":\"2025-09-16T08:00:53+00:00\",\"dateModified\":\"2025-09-16T08:56:16+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/sitpharma.com\\\/italy\\\/en\\\/news-eng\\\/sit-pharma-acquires-ostidil-d3-and-keforal\\\/#breadcrumb\"},\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/sitpharma.com\\\/italy\\\/en\\\/news-eng\\\/sit-pharma-acquires-ostidil-d3-and-keforal\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\\\/\\\/sitpharma.com\\\/italy\\\/en\\\/news-eng\\\/sit-pharma-acquires-ostidil-d3-and-keforal\\\/#primaryimage\",\"url\":\"https:\\\/\\\/sitpharma.com\\\/italy\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2025\\\/04\\\/press-release-Sit-Pharma.jpg\",\"contentUrl\":\"https:\\\/\\\/sitpharma.com\\\/italy\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2025\\\/04\\\/press-release-Sit-Pharma.jpg\",\"width\":1920,\"height\":1080,\"caption\":\"Copertina Press Release di SIT Pharma\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/sitpharma.com\\\/italy\\\/en\\\/news-eng\\\/sit-pharma-acquires-ostidil-d3-and-keforal\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/sitpharma.com\\\/italy\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SIT PHARMA acquires OSTIDIL-D3 and KEFORAL\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/sitpharma.com\\\/italy\\\/#website\",\"url\":\"https:\\\/\\\/sitpharma.com\\\/italy\\\/\",\"name\":\"Sitpharma - Italia\",\"description\":\"sitpharma\",\"publisher\":{\"@id\":\"https:\\\/\\\/sitpharma.com\\\/italy\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/sitpharma.com\\\/italy\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"it-IT\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/sitpharma.com\\\/italy\\\/#organization\",\"name\":\"Sitpharma - Italia\",\"url\":\"https:\\\/\\\/sitpharma.com\\\/italy\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\\\/\\\/sitpharma.com\\\/italy\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/sitpharma.com\\\/italy\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2023\\\/06\\\/sit-bianco-1.png\",\"contentUrl\":\"https:\\\/\\\/sitpharma.com\\\/italy\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2023\\\/06\\\/sit-bianco-1.png\",\"width\":2784,\"height\":735,\"caption\":\"Sitpharma - Italia\"},\"image\":{\"@id\":\"https:\\\/\\\/sitpharma.com\\\/italy\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/sit-srl\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/sitpharma.com\\\/italy\\\/#\\\/schema\\\/person\\\/351eae45371e9c78d10686173578ea00\",\"name\":\"pipestaff\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f121ed4056065399350d3f091eee26890d5afa8d002f1c7cf6594d319f8fd262?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f121ed4056065399350d3f091eee26890d5afa8d002f1c7cf6594d319f8fd262?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f121ed4056065399350d3f091eee26890d5afa8d002f1c7cf6594d319f8fd262?s=96&d=mm&r=g\",\"caption\":\"pipestaff\"},\"url\":\"https:\\\/\\\/sitpharma.com\\\/italy\\\/author\\\/pipestaff\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"SIT PHARMA acquires OSTIDIL-D3 and KEFORAL - Sitpharma - Italia","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/sitpharma.com\/italy\/en\/news-eng\/sit-pharma-acquires-ostidil-d3-and-keforal\/","og_locale":"it_IT","og_type":"article","og_title":"SIT PHARMA acquires OSTIDIL-D3 and KEFORAL","og_description":"SIT PHARMA is pleased to announce the acquisition of OSTIDIL-D3 and KEFORAL","og_url":"https:\/\/sitpharma.com\/italy\/en\/news-eng\/sit-pharma-acquires-ostidil-d3-and-keforal\/","og_site_name":"Sitpharma - Italia","article_published_time":"2025-09-16T08:00:53+00:00","article_modified_time":"2025-09-16T08:56:16+00:00","og_image":[{"width":1920,"height":1080,"url":"https:\/\/sitpharma.com\/italy\/wp-content\/uploads\/sites\/2\/2025\/04\/press-release-Sit-Pharma.jpg","type":"image\/jpeg"}],"author":"pipestaff","twitter_card":"summary_large_image","twitter_misc":{"Scritto da":"pipestaff","Tempo di lettura stimato":"2 minuti"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/sitpharma.com\/italy\/en\/news-eng\/sit-pharma-acquires-ostidil-d3-and-keforal\/#article","isPartOf":{"@id":"https:\/\/sitpharma.com\/italy\/en\/news-eng\/sit-pharma-acquires-ostidil-d3-and-keforal\/"},"author":{"name":"pipestaff","@id":"https:\/\/sitpharma.com\/italy\/#\/schema\/person\/351eae45371e9c78d10686173578ea00"},"headline":"SIT PHARMA acquires OSTIDIL-D3 and KEFORAL","datePublished":"2025-09-16T08:00:53+00:00","dateModified":"2025-09-16T08:56:16+00:00","mainEntityOfPage":{"@id":"https:\/\/sitpharma.com\/italy\/en\/news-eng\/sit-pharma-acquires-ostidil-d3-and-keforal\/"},"wordCount":329,"publisher":{"@id":"https:\/\/sitpharma.com\/italy\/#organization"},"image":{"@id":"https:\/\/sitpharma.com\/italy\/en\/news-eng\/sit-pharma-acquires-ostidil-d3-and-keforal\/#primaryimage"},"thumbnailUrl":"https:\/\/sitpharma.com\/italy\/wp-content\/uploads\/sites\/2\/2025\/04\/press-release-Sit-Pharma.jpg","articleSection":["News-eng"],"inLanguage":"it-IT"},{"@type":"WebPage","@id":"https:\/\/sitpharma.com\/italy\/en\/news-eng\/sit-pharma-acquires-ostidil-d3-and-keforal\/","url":"https:\/\/sitpharma.com\/italy\/en\/news-eng\/sit-pharma-acquires-ostidil-d3-and-keforal\/","name":"SIT PHARMA acquires OSTIDIL-D3 and KEFORAL - Sitpharma - Italia","isPartOf":{"@id":"https:\/\/sitpharma.com\/italy\/#website"},"primaryImageOfPage":{"@id":"https:\/\/sitpharma.com\/italy\/en\/news-eng\/sit-pharma-acquires-ostidil-d3-and-keforal\/#primaryimage"},"image":{"@id":"https:\/\/sitpharma.com\/italy\/en\/news-eng\/sit-pharma-acquires-ostidil-d3-and-keforal\/#primaryimage"},"thumbnailUrl":"https:\/\/sitpharma.com\/italy\/wp-content\/uploads\/sites\/2\/2025\/04\/press-release-Sit-Pharma.jpg","datePublished":"2025-09-16T08:00:53+00:00","dateModified":"2025-09-16T08:56:16+00:00","breadcrumb":{"@id":"https:\/\/sitpharma.com\/italy\/en\/news-eng\/sit-pharma-acquires-ostidil-d3-and-keforal\/#breadcrumb"},"inLanguage":"it-IT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/sitpharma.com\/italy\/en\/news-eng\/sit-pharma-acquires-ostidil-d3-and-keforal\/"]}]},{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/sitpharma.com\/italy\/en\/news-eng\/sit-pharma-acquires-ostidil-d3-and-keforal\/#primaryimage","url":"https:\/\/sitpharma.com\/italy\/wp-content\/uploads\/sites\/2\/2025\/04\/press-release-Sit-Pharma.jpg","contentUrl":"https:\/\/sitpharma.com\/italy\/wp-content\/uploads\/sites\/2\/2025\/04\/press-release-Sit-Pharma.jpg","width":1920,"height":1080,"caption":"Copertina Press Release di SIT Pharma"},{"@type":"BreadcrumbList","@id":"https:\/\/sitpharma.com\/italy\/en\/news-eng\/sit-pharma-acquires-ostidil-d3-and-keforal\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/sitpharma.com\/italy\/"},{"@type":"ListItem","position":2,"name":"SIT PHARMA acquires OSTIDIL-D3 and KEFORAL"}]},{"@type":"WebSite","@id":"https:\/\/sitpharma.com\/italy\/#website","url":"https:\/\/sitpharma.com\/italy\/","name":"Sitpharma - Italia","description":"sitpharma","publisher":{"@id":"https:\/\/sitpharma.com\/italy\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/sitpharma.com\/italy\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"it-IT"},{"@type":"Organization","@id":"https:\/\/sitpharma.com\/italy\/#organization","name":"Sitpharma - Italia","url":"https:\/\/sitpharma.com\/italy\/","logo":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/sitpharma.com\/italy\/#\/schema\/logo\/image\/","url":"https:\/\/sitpharma.com\/italy\/wp-content\/uploads\/sites\/2\/2023\/06\/sit-bianco-1.png","contentUrl":"https:\/\/sitpharma.com\/italy\/wp-content\/uploads\/sites\/2\/2023\/06\/sit-bianco-1.png","width":2784,"height":735,"caption":"Sitpharma - Italia"},"image":{"@id":"https:\/\/sitpharma.com\/italy\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/sit-srl\/"]},{"@type":"Person","@id":"https:\/\/sitpharma.com\/italy\/#\/schema\/person\/351eae45371e9c78d10686173578ea00","name":"pipestaff","image":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/secure.gravatar.com\/avatar\/f121ed4056065399350d3f091eee26890d5afa8d002f1c7cf6594d319f8fd262?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/f121ed4056065399350d3f091eee26890d5afa8d002f1c7cf6594d319f8fd262?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f121ed4056065399350d3f091eee26890d5afa8d002f1c7cf6594d319f8fd262?s=96&d=mm&r=g","caption":"pipestaff"},"url":"https:\/\/sitpharma.com\/italy\/author\/pipestaff\/"}]}},"_links":{"self":[{"href":"https:\/\/sitpharma.com\/italy\/wp-json\/wp\/v2\/posts\/11401","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sitpharma.com\/italy\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sitpharma.com\/italy\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sitpharma.com\/italy\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/sitpharma.com\/italy\/wp-json\/wp\/v2\/comments?post=11401"}],"version-history":[{"count":8,"href":"https:\/\/sitpharma.com\/italy\/wp-json\/wp\/v2\/posts\/11401\/revisions"}],"predecessor-version":[{"id":11423,"href":"https:\/\/sitpharma.com\/italy\/wp-json\/wp\/v2\/posts\/11401\/revisions\/11423"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sitpharma.com\/italy\/wp-json\/wp\/v2\/media\/11016"}],"wp:attachment":[{"href":"https:\/\/sitpharma.com\/italy\/wp-json\/wp\/v2\/media?parent=11401"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sitpharma.com\/italy\/wp-json\/wp\/v2\/categories?post=11401"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sitpharma.com\/italy\/wp-json\/wp\/v2\/tags?post=11401"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}